Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
Antineoplastic Agents, Phytogenic
Antineoplastic Combined Chemotherapy Protocols
The addition of four cycles of paclitaxel after the completion of a standard course of CA improves the disease-free and overall survival of patients with early breast cancer.
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency